Keywords: Parkinson's disease, Treatment variations, France, Germany, Italy, Spain, UK, GlaxoSmithKline, Reqip, Boehringer Ingelheim, Mirapex, Teva, Lundbeck, Azilect
Variations in Parkinson's disease treatment among prescribers in France, Germany, Italy, Spain and the UK
Article | 02 December 2010
When comparing dopamine agonist use for Parkinson's disease, more frequent use of once-daily formulations of Requip (GlaxoSmithKline's ropinirole, Requip XL/ ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
